Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system

Abstract

The intestinal lymphatic system plays an important role in the pathophysiology of multiple diseases including lymphomas, cancer metastasis, autoimmune diseases, and human immunodeficiency virus (HIV) infection. It is thus an important compartment for delivery of drugs in order to treat diseases associated with the lymphatic system. Lipophilic prodrug approaches have been used in the past to take advantage of the intestinal lymphatic transport processes to deliver drugs to the intestinal lymphatics. Most of the approaches previously adopted were based on very bulky prodrug moieties such as those mimicking triglycerides (TG). We now report a study in which a lipophilic prodrug approach was used to efficiently deliver bexarotene (BEX) and retinoic acid (RA) to the intestinal lymphatic system using activated ester prodrugs. A range of carboxylic ester prodrugs of BEX were designed and synthesised and all of the esters showed improved association with chylomicrons, which indicated an improved potential for delivery to the intestinal lymphatic system. The conversion rate of the prodrugs to BEX was the main determinant in delivery of BEX to the intestinal lymphatics, and activated ester prodrugs were prepared to enhance the conversion rate. As a result, an 4-(hydroxymethyl)-1,3-dioxol-2-one ester prodrug of BEX was able to increase the exposure of the mesenteric lymph nodes (MLNs) to BEX 17-fold compared to when BEX itself was administered. The activated ester prodrug approach was also applied to another drug, RA, where the exposure of the MLNs was increased 2.4-fold through the application of a similar cyclic activated prodrug. Synergism between BEX and RA was also demonstrated in vitro by cell growth inhibition assays using lymphoma cell lines. In conclusion, the activated ester prodrug approach results in efficient delivery of drugs to the intestinal lymphatic system, which could benefit patients affected by a large number of pathological conditions.

A novel nucleoside rescue metabolic pathway may be responsible for therapeutic effect of orally administered cordycepin

“…Stability of cordycepin in plasma was tested using human and rat plasma by following a previously reported method with minor modifications 44 . Cordycepin was spiked into the plasma at 10 µM and the samples were incubated in a shaking incubator (Thermo Scientific MaxQ4000, Waltham, MA, USA) at 37 °C and shaken at 250 rpm.…”

Quantitative Prediction of Oral Bioavailability of a Lipophilic Antineoplastic Drug Bexarotene Administered in Lipidic Formulation Using a Combined In Vitro Lipolysis/Microsomal Metabolism Approach

“…It has been previously suggested that it is the inherent physicochemical properties of the drug that determines the association ability of the drug with chylomicrons which eventually governs intestinal lymphatic transport 17,31 . The intestinal lymphatic transport of BEX, with its low chylomicron association reported previously 32 , was not affected by LBDDS. It confirms the relevance of application of liver microsomal stability in bioavailability prediction as minimal lymphatic transport would mean that hepatic first-pass effect would be applied to BEX 8 .…”

Strawberry Decreases Intraluminal and Intestinal Wall Hydrolysis of Testosterone Undecanoate

“…In this study, we assessed the intestinal lymphatic transport potential of TU by measuring the association with plasma-derived human CM. This approach was previously shown to provide accurate estimate for the intestinal lymphatic transport of lipophilic compounds [ 18 , 21 , 28 ]. The high association value of TU with CM in this study (84.3%) suggests considerable intestinal lymphatic transport and improved bioavailability following oral administration in conditions that promote CM assembly, particularly with long-chain triglyceride-rich lipids.…”

“…FaSSIF was prepared according to the literature [ 17 ]. The stability of TU in FaSSIF/ES was performed as described in the literature [ 18 , 19 ]. The reaction medium (1 mL) was incubated at 37 °C for 5 min prior to the experiment.…”